Passkey Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Kendall Sq Bldg 200 Ste 1, Cambridge, ...Website
www.passkeytx.comRevenue
<$5 MillionIndustry
About Passkey Therapeutics
Passkey Therapeutics utilizes its Locksmith platform, powered by AI, to identify synergistic drug combinations from approved assets using human genetic data, facilitating clinical-stage innovation. The company aims to unlock clinic-ready combinations of drugs that can treat new indications with existing assets, bypassing traditional preclinical development. Their focus is on addressing significant complex diseases with unmet needs, leveraging a wealth of biological synergies. Passkey Therapeutics partners with pharmaceutical companies to validate these combinations in clinical trials, sharing in the success of their innovative approaches.Explore more
Passkey Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Passkey Therapeutics
Compare insights from companies similar to Passkey Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$9.1M
11-50
Private
$220M
2020
Mehrdad HamadaniChief Technology Officer & Executive VP, Engineering, Artificial Intelligence & Operations
Passkey Therapeutics Tech Stack
A closer look at the technologies used by Passkey Therapeutics
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Passkey Therapeutics
Sign Up For FreeTo access detailed company insights
Passkey Therapeutics utilizes its Locksmith platform, powered by AI, to identify synergistic drug combinations from approved assets using human genetic data, facilitating clinical-stage innovation. The company aims to unlock clinic-ready combinations of drugs that can treat new indications with existing assets, bypassing traditional preclinical dev... Read More
